tirzepatide cognitive function A newly published case series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or Tirzepatide administration improves cognitive impairment

Kristal, A

Retatrutide: The triple-agonist still in trials Retatrutide adds a third receptor to the mix: GLP-1, GIP, and glucagon

In the studies examined in this review (excluding case series and case reports), the use of semaglutide and tirzepatide [administered at different doses and for varying durations (from 12 weeks to 50 months)] in T1D patients was associated with average/median reductions in HbA1c values of about 0.200.60% and 0.450.90%, respectively

Tirzepatide produces an average loss of about 46 pounds

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. International Journal of Obesity